Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Porsolt, JSW in Research Services Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Porsolt, JSW in Research Services Pact

Porsolt and JSW sign a strategic collaboration agreement to co-market contract research services.

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Porsolt and JSW Lifesciences have signed a strategic collaboration agreement to co-market complementary contract research services. Porsolt offers specialized preclinical pharmacology services across many disease areas and physiological systems and processes. JSW brings significant experience in performing a wide range of in vitro, behavioral, histopathology, and immunohistochemistry studies. 

Using standardized and innovative techniques, Porsolt offers services in both efficacy and GLP safety pharmacology. JSW’s extensive capabilities include molecular biological techniques, protein expression systems, monoclonal antibodies and exclusive access to transgenic animal models of neurodegenerative diseases. In addition JSW offers full clinical research services from phase I to phase IV.

“We are excited about working with Porsolt, a leading CRO with a global reputation and presence in numerous different markets. This agreement allows us to combine contract research services, proprietary disease models and technologies, drug discovery capabilities, and provide an expanded portfolio of services for the benefit of the pharma, biotech and research communities,” said Dr. Manfred Windisch, president and chief executive officer of Austria-based JSW.

“JSW’s unique access to exclusive transgenic models of human disease, coupled with their in vitro capabilities, makes them a perfect partner for Porsolt. JSW will become one of our most significant strategic partners, further establishing us as the market leader in fully integrated lead optimization drug discovery services,” commented Dr. Mark Duxon, Porsolt’s chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics